• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4617274)   Today's Articles (4730)   Subscriber (49396)
For: Selvaggi G, Wu Y, Wang Z, Wu G, Poddubskaya E, Reck M, Mok T, Chiappori A, Lee D, Breder V, Orlov S, Cicin I, Cheng Y, Liu Y, Fan Y, Zhou J, Liang C, Mao L, Horn L, Wakelee H. FP14.12 Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK–Positive NSCLC Patients: eXalt3. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.155] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Number Cited by Other Article(s)
1
Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study. J Thorac Oncol 2021;16:1959-1963. [PMID: 34265433 DOI: 10.1016/j.jtho.2021.06.023] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Revised: 06/12/2021] [Accepted: 06/14/2021] [Indexed: 11/23/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA